We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Dermatology

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

MedXY Editorial Team•Oct 24, 2025•Dermatology
alopecia areataBaricitinibJAK inhibitorPediatric Dermatology

Highlight

– Baricitinib achieved significant hair regrowth (scalp, eyebrows, and eyelashes) in adolescents with severe alopecia areata (AA) after one year27s treatment.
– In patients aged 12 to less than 18 years, 54.1% receiving 4 mg daily attained 80% scalp hair coverage, with up to 80% response in those with recent-onset disease.
– Safety profile in adolescents was consistent with prior adult studies, with no new safety signals over 12 months.
– Eli Lilly plans to file regulatory submissions globally for label expansion and will initiate enrollment of younger children (6 to <12 years) in upcoming trials.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Durability of β-Cell Function After Cessation of Baricitinib Immunotherapy in New-Onset Type 1 DiabetesBaricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.Aug 22, 2026Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical TrialsTwo large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.Aug 17, 2026Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational InsightsThis review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging clAug 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial
The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alte
Mar 6, 2026
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head TrialA randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both treMar 5, 2026
Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and BaricitinibThis study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.Mar 5, 2026